Learn from the best in industry
guests: Rakesh Nagarajan, MD, PhD
To support comprehensive interpretation of in vitro diagnostic assays, PierianDx has developed a robust approach for genomics knowledge sharing and inferencing. Driven by a rich set of curated and rationalized content of medical interpretations, clinical practice guidelines, FDA therapeutics and clinical trials, this approach provides well-vetted interpretations and classifications of genomic variants for in vitro diagnostics.
guests: Shalini Verma, MD, FCAP
Broader adoption of next-generation sequencing-based cancer testing reveals the challenges associated with variant interpretation and underscores the need to standardize results across molecular pathology labs. In this informative workshop, we review the guidelines developed by the Association for Molecular Pathology (AMP) and describe how to put them into practice using real clinical cases.
guests: Rakesh Nagarajan, MD, PhD
Clinical NGS has been widely adopted as Laboratory Derived Tests (LDTs). NGS-based in vitro diagnostics (IVD) recently gained FDA approval with many others now in process. These IVD assays facilitate broad, widespread adoption of NGS-based testing globally in cancer and other complex conditions that require timely, accurate diagnoses and treatment. To support comprehensive interpretation of these assays, we have developed the PierianDx KnowledgeBase. Driven by the richest set of curated and rationalized content of medical interpretations, clinical practice guidelines, FDA therapeutics and clinical trials, the PierianDx KnowledgeBase offers the most well-vetted interpretations and classifications of genomic variants for IVD use.
guests: Shalini Verma, MD, FCAP; and Karl Voelkerding, MD, FCAP
Optimism for next generation sequencing (NGS) technologies to be used in a clinical setting quickly turns to numerous conversations about the challenges involved. In this webinar, we discuss the CAP (College of American Pathologists) Distributive Model and how your organization can leverage it to rapidly and economically conduct or scale clinical NGS testing.
guests: Shalini Verma, MD, FCAP; Andy Bredemeyer, PhD
Broader adoption of next-generation sequencing-based cancer testing reveals the challenges associated with variant interpretation and underscores the need to standardize results across molecular pathology labs. Guidelines developed by the Association for Molecular Pathology (AMP) with representation from key institutions, including ACMG, outline a system to categorize sequence variations in cancer.
guests: Eric Loo, MD and Rakesh Nagarjan, MD, PhD
Dartmouth-Hitchcock has experienced nearly 40% savings by bringing NGS testing in-house. A recent AMP study using non-small cell lung cancer as an example cites $2.7 million in anticipated savings. In-house NGS testing is the foundation of any modern precision medicine program. It can have a profound effect on patient care. And, as these examples show, a strong business case can be made.
guests: Ravindra Kolhe, MD, PhD; Karen L. Kaul, MD, PhD; Theresa Ann Boyle, MD, PhD; Mani S. Mahadevan, MD; and Nikoletta Sidiropoulos, MD
How do recent coverage decisions on NGS testing affect you? For academic centers, leading cancer institutions, and essential community cancer centers that have CLIA-certified laboratories providing validated laboratory developed NGS-based tests, the policy would supersede existing local coverage policies for most of those tests and limit Medicare beneficiaries’ access to a single test.
guests: Gregory Tsongalis, MD; Anthony Magliocco, MD; and Ravindra Kolhe, MD
The TST170 next-generation sequencing-based panel targets single nucleotide variants, indels, gene amplifications, gene fusions, splice variants, mRNA expression, and mRNA isoform detection found in 170 cancer-related genes and also calculates metrics such as tumor mutation burden and determines evidence for microsatellite instability. Panelists discuss the design of the assay, data analytics, and reasons behind their selection of the TST170 assay, and will share details of how it is being utilized within their organizations.
guest: Rakesh Nagarajan
PierianDx accelerates precision medicine by offering one space to handle a range of genomic testing, from somatic to constitutional, from small panels to whole exome or genome. During this webinar, PierianDx Chief Biomedical Informatics Officer Dr. Rakesh Nagarajan will provide an overview of CGW and illustrate how the industry leading platform seamlessly manages genomic data and workflow for each case, from variant analysis and classification to interpretation, reporting and final sign out.
guest: Anthony Magliocco, MD
Building a world-class precision medicine program takes the right mix of innovative leadership, advanced technology, clinical acumen, and strategic partnerships. During this webinar, Dr. Anthony Magliocco, the Chair of Anatomic Pathology at Moffitt Cancer Center, will share the Moffitt success story – from its pioneering inception to being one of only 47 Comprehensive Cancer Centers as designated by the National Cancer Institute.
guest: Rakesh Nagarajan
The success of any precision medicine program involves the right combination of personnel and technology. PierianDx’s Clinical Genomicist Workspace (CGW) has been the technology platform of choice for clinical labs to seamlessly manage their genomic data and workflow from variant analysis and classification to interpretation, reporting and final sign out. However, the right strategy and clinical resources at the validation and interpretation stages are just as important to that success. During this webinar, PierianDx Chief Bioinformatics Officer Rakesh Nagarajan will discuss ways clinical labs can improve validation and interpretation approaches to enhance report actionability, relevance and throughput.
guest: Nikoletta Sidiropoulos, MD
Dr. Sidiropoulos shared her experiences and lessons learned as she works to evolve the university’s precision medicine program. Specific examples were shared on how to improve clinical lab workflow, starting with DNA or RNA samples and ending with a report of relevant variants to assist in clinical decision-making. By the end of this webinar, participants will have some real-world examples of how to accelerate their own personalized medicine initiatives from clinical experts in the field.
guests: Allie Grossman, MD; Karl Voelkerding, MD, FCAP; and Rakesh Nagarajan, MD, PhD
This interactive roundtable discusses established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting. An expert panel of leading pathologists, medical geneticists, and researchers will address genomic testing advances in two thematic areas: 1) scientific and clinical trends in reporting, and 2) clinical lab operations and quality management.